51st Annual Meeting of the American Aging Association

美国老龄化协会第 51 届年会

基本信息

  • 批准号:
    10602831
  • 负责人:
  • 金额:
    $ 5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-12-15 至 2023-11-30
  • 项目状态:
    已结题

项目摘要

We are requesting funds to support the 51st Annual Meeting of the American Aging Association (AGE) that will take place on June 5-10, 2023 in Oklahoma City, OK. The 51st Annual AGE Meeting will be held in conjunction with a Nathan Shock Centers of Excellence in the Basic Biology of Aging Symposium (June 6). Since its first conference in 1971, the American Aging Association has been the only scientific society in the United States focused solely on the biology of aging. The annual AGE meeting is one of the premier meetings in biogerontological research and serves as a critical mechanism by which AGE advances its mission to promote biomedical aging studies that target increasing the functional life span of humans, to keep the public informed on these activities, to increase knowledge of biogerontology among health care professionals, and to foster the scientific and professional career development of AGE trainees and scientific members. The primary goal of the conference is to convene senior and junior scientists in a forum where the latest discoveries in aging research are discussed and debated, to highlight exciting new research in the field, and to promote the emergence of new ideas and collaborative activities among participants. The theme for the AGE 51st annual meeting is “The Evolution of Aging Research –How the Past and Present Direct Us to the Future”. The invited speakers include prominent established scientists, early career investigators, and trainees, all of whom will be selected based on the quality and impact of their science. We have planned 9 non-competing oral sessions that will be held along with three special lectures, one of which will be open to the general public. Fostering the next generation of biogerontologists is a primary goal of the society; therefore, one of the sessions will be organized in its entirety by the Trainee Chapter of AGE. In addition, we have chosen to have two speakers in each of the sessions as early career investigators or trainees selected from submitted abstracts. Two poster sessions are planned that will not compete with oral presentations. Abstracts will be reviewed and scored and the top 40 poster presenters will be given the opportunity to present their posters in a two-minute oral “poster pitch” during the regular sessions. Gender parity will be achieved and approximately 50% of all speakers will be early career or trainees and we will have at least 20% from underrepresented minority groups. We expect that the meeting will be held in person with a live-streamed virtual component. . AGE has experience with both fully virtual and hybrid meetings, and will be prepared to switch to an entirely virtual format if the need arises. We will adhere to established meeting guidelines, including ensuring that day care opportunities and special need access are provided.
我们正在申请资金支持美国老龄化协会 (AGE) 第 51 届年会,该会议将 第 51 届 AGE 年度会议将于 2023 年 6 月 5 日至 10 日在俄克拉荷马州俄克拉荷马城举行。 与 Nathan Shock 衰老基础生物学卓越中心研讨会(6 月 6 日)。 1971年的会议上,美国老龄化协会是美国唯一的科学学会 年度 AGE 会议仅关注衰老生物学,是世界上最重要的会议之一。 生物老年学研究,并作为 AGE 推进其使命的关键机制,以促进 旨在延长人类功能寿命的生物医学衰老研究,以使公众了解情况 在这些活动中,增加医疗保健专业人员的生物老年学知识,并促进 AGE 学员和科学成员的科学和专业职业发展是 AGE 的首要目标。 会议是召集高级和初级科学家进行论坛,讨论衰老研究的最新发现 进行讨论和辩论,以突出该领域令人兴奋的新研究,并促进新研究的出现 AGE第51届年会的主题是“The”。 衰老研究的演变——过去和现在如何引导我们走向未来”。 杰出的知名科学家、早期职业研究人员和实习生,所有这些人都将根据 我们计划同时举行 9 场非竞争性口头会议。 举办三场特别讲座,其中一场将向公众开放,培养下一代。 生物老年学家是该协会的首要目标;因此,将举办一次完整的会议; 此外,我们在每场会议中选择了两名发言人。 计划从提交的摘要中选出早期职业研究者或实习生。 不会与口头报告竞争 摘要将被评审和评分,并选出前 40 名海报展示者。 将有机会在常规活动期间通过两分钟的口头“海报推介”展示他们的海报 会议将实现性别平等,大约 50% 的演讲者将是职业生涯早期或实习生。 我们预计会议将至少有 20% 来自代表性不足的少数群体。 AGE 亲自参与直播虚拟组件,拥有完全虚拟和混合的经验。 会议,并准备在需要时切换为虚拟形式,我们将坚持这样做。 制定会议准则,包括确保提供日托机会和特殊需要的机会 假如。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HOLLY VAN REMMEN其他文献

HOLLY VAN REMMEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HOLLY VAN REMMEN', 18)}}的其他基金

A novel role for oxidized lipid mediators as effectors of muscle atrophy and weakness in aging
氧化脂质介质作为衰老过程中肌肉萎缩和无力效应物的新作用
  • 批准号:
    10710399
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
A novel role for oxidized lipid mediators as effectors of muscle atrophy and weakness in aging
氧化脂质介质作为衰老过程中肌肉萎缩和无力效应物的新作用
  • 批准号:
    10608413
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
Testing OKN-007 as a potential intervention for ALS
测试 OKN-007 作为 ALS 的潜在干预措施
  • 批准号:
    10513312
  • 财政年份:
    2021
  • 资助金额:
    $ 5万
  • 项目类别:
Testing OKN-007 as a potential intervention for ALS
测试 OKN-007 作为 ALS 的潜在干预措施
  • 批准号:
    10259079
  • 财政年份:
    2021
  • 资助金额:
    $ 5万
  • 项目类别:
BLR&D Research Career Scientist Award Application
BLR
  • 批准号:
    10451499
  • 财政年份:
    2020
  • 资助金额:
    $ 5万
  • 项目类别:
BLR&D Research Career Scientist Award Application
BLR
  • 批准号:
    10618299
  • 财政年份:
    2020
  • 资助金额:
    $ 5万
  • 项目类别:
Activation of the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) as a Therapeutic Intervention for Sarcopenia
激活肌浆/内质网钙 ATP 酶 (SERCA) 作为肌肉减少症的治疗干预措施
  • 批准号:
    9912630
  • 财政年份:
    2019
  • 资助金额:
    $ 5万
  • 项目类别:
Activation of the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) as a Therapeutic Intervention for Sarcopenia
激活肌浆/内质网钙 ATP 酶 (SERCA) 作为肌肉减少症的治疗干预措施
  • 批准号:
    10166596
  • 财政年份:
    2019
  • 资助金额:
    $ 5万
  • 项目类别:
Activation of the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) as a Therapeutic Intervention for Sarcopenia
激活肌浆/内质网钙 ATP 酶 (SERCA) 作为肌肉减少症的治疗干预措施
  • 批准号:
    10454863
  • 财政年份:
    2019
  • 资助金额:
    $ 5万
  • 项目类别:
Summer Training Course in Experimental Aging Research
实验老化研究暑期培训课程
  • 批准号:
    10560479
  • 财政年份:
    2018
  • 资助金额:
    $ 5万
  • 项目类别:

相似海外基金

Exercise adherence and cognitive decline: Engaging with the Black community to develop and test a goal-setting and exercise intensity intervention
运动坚持和认知能力下降:与黑人社区合作制定和测试目标设定和运动强度干预措施
  • 批准号:
    10767102
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
Examining the relationship between death attitude and AD completion and attitude among older Chinese Americans
研究老年华裔美国人的死亡态度与 AD 完成度和态度之间的关系
  • 批准号:
    10575699
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
Engaging Underrepresented Racial/Ethnic Minority Students in Aging Research
让少数族裔学生参与老龄化研究
  • 批准号:
    10627635
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
American Society for Neurochemistry Annual Meeting 2023
2023 年美国神经化学学会年会
  • 批准号:
    10686706
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
Student Transformative Experiences to Progress Undergraduate/Graduate Professionals (STEP-UP) for cancer prevention
学生通过变革性经验提升本科/研究生专业水平 (STEP-UP) 以预防癌症
  • 批准号:
    10711389
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了